Home
ACE Reports
All Specialties All Specialties All Specialties Arthroplasty Arthroplasty Arthroplasty Evidence Based Medicine Evidence Based Medicine Evidence Based Medicine Foot & Ankle Foot & Ankle Foot & Ankle General Orthopaedics General Orthopaedics General Orthopaedics Hand & Wrist Hand & Wrist Hand & Wrist Metabolic Disorders Metabolic Disorders Metabolic Disorders Osteoarthritis Osteoarthritis Osteoarthritis Pediatric Orthopaedics Pediatric Orthopaedics Pediatric Orthopaedics Peri-Operative Peri-Operative Peri-Operative Physical Therapy & Rehab Physical Therapy & Rehab Physio & Rehab Shoulder & Elbow Shoulder & Elbow Shoulder & Elbow Spine Spine Spine Sports Medicine Sports Medicine Sports Medicine Trauma Trauma Trauma Tumour Tumour Tumour Author Interviews Author Interviews Author Interview Conference Report Conference Report Conference Reports
Original Content
News
Multimedia
About
Search
Home
ACE Reports
Arthroplasty Evidence Based Medicine Foot & Ankle General Orthopaedics Hand & Wrist Metabolic Disorders Osteoarthritis Pediatric Orthopaedics Peri-Operative Physical Therapy & Rehab Shoulder & Elbow Spine Sports Medicine Trauma Tumour Author Interviews Conference Report
Original Content
News
Multimedia
About
Search
Previous Ace Report Effect of joint biomarkers on outcome in knee OA treatment with HA and CS indeterminate Next Ace Report Effect of joint biomarkers on outcome in knee OA treatment with HA and CS indeterminate
Ace Report Cover
Osteoarthritis
Zoledronic acid has no continued benefit beyond 6 years for osteoporosis
Reprints
Cite This
Reprints
Cite This
AceReport Image
Osteoarthritis
Zoledronic acid has no continued benefit beyond 6 years for osteoporosis
J Bone Miner Res. 2015 May;30(5):934-44.
Contributing Authors

DM Black IR Reid JA Cauley F Cosman PC Leung P Lakatos K Lippuner SR Cummings TF Hue A Mukhopadhyay M Tan RP Aftring R Eastell

One hundred and ninety patients were randomized to receive either continued zolderonic acid (ZOL) treatment or were switched to a placebo after six years of ZOL treatment for osteoporosis. Patients received treatment for an additional 3 years to determine continued efficacy and safety of ZOL. Results found that there was no significant benefit to continued ZOL treatment. Additionally, there was a significantly higher rate of arrhythmia in patients receiving ZOL.

Unlock the full article

Get unlimited access to OrthoEvidence with a free trial
Start Trial

Critical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics

Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics

Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions

Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics

Or continue reading this full article
Register Now
AskOE
Search
Close Search Window
Welcome Back!
Forgot Password?
Create an Account

Account will be affiliated with

OR
Forgot Password?
OR
Check your email

If an account exists with the provided email address, a password reset email will be sent to you. If you don't see the email, please check your spam or junk folder.

For further assistance, contact our support team.

Cite this Ace Report

OrthoEvidence. Zoledronic acid has no continued benefit beyond 6 years for osteoporosis . ACE Report. 2015;5(12):58. Available from: https://myorthoevidence.com/AceReport/Report/

Copy Citation
Share this Ace Report